Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Equity Ratio: 2009-2025

Historic Equity Ratio for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to -3.55.

  • Northwest Biotherapeutics' Equity Ratio fell 29.91% to -3.55 in Q3 2025 from the same period last year, while for Sep 2025 it was -3.55, marking a year-over-year decrease of 29.91%. This contributed to the annual value of -3.54 for FY2024, which is 49.77% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Equity Ratio stood at -3.55, which was down 4.47% from -3.40 recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Equity Ratio high stood at -1.70 for Q1 2023, and its period low was -42.73 during Q3 2023.
  • In the last 3 years, Northwest Biotherapeutics' Equity Ratio had a median value of -2.73 in 2024 and averaged -6.46.
  • In the last 5 years, Northwest Biotherapeutics' Equity Ratio plummeted by 1,120.86% in 2023 and then spiked by 93.61% in 2024.
  • Over the past 5 years, Northwest Biotherapeutics' Equity Ratio (Quarterly) stood at -3.09 in 2021, then slumped by 32.46% to -4.09 in 2022, then skyrocketed by 42.28% to -2.36 in 2023, then plummeted by 49.77% to -3.54 in 2024, then fell by 29.91% to -3.55 in 2025.
  • Its Equity Ratio stands at -3.55 for Q3 2025, versus -3.40 for Q2 2025 and -3.62 for Q1 2025.